SCHEMBL2472483

SCHEMBL2472483

COSc1ccc(OC)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA7 P43166 2/20 0.58
CA9 Q16790 2/20 0.58
CA12 O43570 1/20 0.58
CA14 Q9ULX7 1/20 0.58
CYP1A1 P04798 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP1B1 Q16678 1/20 0.48
ACHE P22303 1/20 0.48
TDP1 Q9NUW8 3/20 0.46
MAPK1 P28482 2/20 0.46
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Sulfide SCHEMBL17008163 0.97 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL2220176 0.84 CA1 (0.58) CA1CA2CA7CA9CA12
SCHEMBL17008159 0.81 ALDH1A1 (0.41) CA1CA2CA7CA9CA12
SCHEMBL5492607 0.80 CA12 (0.33) CA1CA2CA7CA9CA12
SCHEMBL116400 0.79 CA1 (0.58) CA1CA2CA7CA9CA12
SCHEMBL10407394 0.78 MAPT (0.44) CYP1A2TDP1MAPK1ALDH1A1KDM4E
SCHEMBL438406 0.78 CA1 (0.65) CA1CA2CA7CA9CA12
SCHEMBL482369 0.78 CA1 (0.65) CA1CA2CA7CA9CA12
SCHEMBL9544764 0.77 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL19992038 0.77 LTA4H (0.58) CA1CA2MAPK1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834532-B2 Photoinitiators IGH RESINS ITALIA S.R.L. (IT) 2023-12-05 US claimed
CN-115651170-A Preparation of heptazine-based polymer and application of heptazine-based polymer in photocatalytic oxidation of thioether 福州大学 2023-01-31 CN claimed
US-20220098333-A1 PHOTOINITIATORS IGM RESINS ITALIA S.R.L. (IT) 2022-03-31 US claimed
EP-3902878-A1 PHOTOINITIATORS IGM Resins Italia S.r.l. (IT) 2021-11-03 EP claimed
WO-2020136522-A1 PHOTOINITIATORS IGM RESINS ITALIA S.R.L. (IT) 2020-07-02 WO claimed
CN-111153837-A Method for preparing sulfoxide compound by catalytic oxidation of thioether with nickel compound 上海应用技术大学 2020-05-15 CN claimed
EP-3902878-B1 PHOTOINITIATORS IGM RESINS ITALIA SRL (IT) 2026-05-06 EP disclosed
US-20250331405-A1 DISPLAY DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2025-10-23 US disclosed
WO-2025073057-A1 METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-04-10 WO disclosed
EP-4455126-A1 LIGHT-MEDIATED AEROBIC OXIDATION METHOD Ecosynth (BE) 2024-10-30 EP disclosed
WO-2024165619-A1 LIGHT-MEDIATED AEROBIC OXIDATION METHOD HG HOLDING B.V. (NL) 2024-08-15 WO disclosed
CN-113666826-B Aryl or heteroaryl methoxylation reaction method 五邑大学 2024-03-26 CN disclosed
US-11905276-B2 Bicyclic compound that acts as CRBN protein regulator MEDSHINE DISCOVERY INC. (CN) 2024-02-20 US disclosed
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases AVENTIS PHARMACEUTICALS INC. 2001-10-25 US disclosed
US-6211199-B1 HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS AVENTIS PHARMACEUTICALS INC. 2001-04-03 US disclosed
US-6194406-B1 HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS AVENTIS PHARMACEUTICALS INC. 2001-02-27 US disclosed
EP-0920425-A1 SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1999-06-09 EP disclosed
EP-0874843-A1 NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1998-11-04 EP disclosed
WO-1997022604-A1 NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-06-26 WO disclosed
WO-1997019074-A1 SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases HRH4, HRH2, HRH1 CA1 1771/4885CA2 1373/4885CA7 2355/4885
US-11905276-B2 Bicyclic compound that acts as CRBN protein regulator CRBN, CRKL, NCOR1 CA1 3580/4885CA2 2618/4885CA7 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.